Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion type Assertion NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_head.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion description "[Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion evidence source_evidence_literature NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion SIO_000772 19204207 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion wasDerivedFrom gad-20150221 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion wasGeneratedBy ECO_0000203 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.